Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-LYN mRNAs with seed-region complementarity refers to a collection of unintended messenger RNA transcripts that are downregulated by RNA interference (RNAi) molecules originally designed to target the LYN kinase. This off-target effect occurs when the seed region of an siRNA or shRNA—typically nucleotides 2 through 7 or 8—binds to complementary sequences in the 3' untranslated regions (UTRs) of non-target mRNAs (Jackson et al., 2003, Nature Biotechnology). This binding mimics the natural regulatory mechanism of microRNAs, leading to the degradation or translational inhibition of these unintended transcripts (Birmingham et al., 2006, Nature Methods). In many instances, these off-target interactions can lead to significant cellular toxicity, a phenomenon termed Death Induced by Survival gene Elimination (DISE), where the simultaneous knockdown of multiple essential survival genes triggers apoptosis (Putzbach et al., 2017, eLife). This is particularly relevant in cancer research, where LYN-targeting siRNAs may appear to have therapeutic efficacy that is actually driven by these non-specific seed-mediated effects. Consequently, these mRNAs represent a major safety concern and a technical challenge in the development of RNAi-based therapeutics, requiring careful sequence design and chemical modifications to minimize unintended gene silencing.
Seed-mediated RNA interference (RNAi) leading to unintended transcript degradation or translational repression.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-LYN mRNAs with seed-region complementarity.